Cholangiopathy as part of post-COVID syndrome

Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rojas, Manuel, Rodríguez, Yhojan, Zapata, Elizabeth, Hernández, Juan Carlos, Anaya, Juan-Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406516/
https://www.ncbi.nlm.nih.gov/pubmed/34485887
http://dx.doi.org/10.1016/j.jtauto.2021.100116
_version_ 1783746520192909312
author Rojas, Manuel
Rodríguez, Yhojan
Zapata, Elizabeth
Hernández, Juan Carlos
Anaya, Juan-Manuel
author_facet Rojas, Manuel
Rodríguez, Yhojan
Zapata, Elizabeth
Hernández, Juan Carlos
Anaya, Juan-Manuel
author_sort Rojas, Manuel
collection PubMed
description Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19.
format Online
Article
Text
id pubmed-8406516
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84065162021-08-31 Cholangiopathy as part of post-COVID syndrome Rojas, Manuel Rodríguez, Yhojan Zapata, Elizabeth Hernández, Juan Carlos Anaya, Juan-Manuel J Transl Autoimmun Case report Liver compromise in critically ill patients with coronavirus disease 2019 (COVID-19) is common but usually transient and self-limited. However, liver tests on some patients continue to show abnormal results. Herein, a 29-year-old patient with clinical and histological features of cholangiopathy is presented. Despite treatment with ursodeoxycholic acid and cholestyramine, bilirubin and transaminase levels remained elevated. This case report raises awareness of the difficulty of managing this condition in patients with COVID-19. Elsevier 2021-08-31 /pmc/articles/PMC8406516/ /pubmed/34485887 http://dx.doi.org/10.1016/j.jtauto.2021.100116 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case report
Rojas, Manuel
Rodríguez, Yhojan
Zapata, Elizabeth
Hernández, Juan Carlos
Anaya, Juan-Manuel
Cholangiopathy as part of post-COVID syndrome
title Cholangiopathy as part of post-COVID syndrome
title_full Cholangiopathy as part of post-COVID syndrome
title_fullStr Cholangiopathy as part of post-COVID syndrome
title_full_unstemmed Cholangiopathy as part of post-COVID syndrome
title_short Cholangiopathy as part of post-COVID syndrome
title_sort cholangiopathy as part of post-covid syndrome
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406516/
https://www.ncbi.nlm.nih.gov/pubmed/34485887
http://dx.doi.org/10.1016/j.jtauto.2021.100116
work_keys_str_mv AT rojasmanuel cholangiopathyaspartofpostcovidsyndrome
AT rodriguezyhojan cholangiopathyaspartofpostcovidsyndrome
AT zapataelizabeth cholangiopathyaspartofpostcovidsyndrome
AT hernandezjuancarlos cholangiopathyaspartofpostcovidsyndrome
AT anayajuanmanuel cholangiopathyaspartofpostcovidsyndrome

Ejemplares similares